• Explore /
  • Poster
  • / Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.

Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.

Abstract Poster

Authors

Dung Le

Dung T. Le

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Dung T. Le , Nilofer Saba Azad , Dan Laheru , Ilene S. Browner , Hao Wang , Jennifer N. Uram , Holly Kemberling , Lei Zheng , Robert Iannone , Evan Friedman , Amy Meister , Ross C. Donehower , Ana De Jesus-Acosta , Luis A. Diaz Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01876511

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3128)

DOI

10.1200/jco.2014.32.15_suppl.tps3128

Abstract #

TPS3128

Poster Bd #

186B

Abstract Disclosures

Similar Posters

First Author: Ana Carneiro

First Author: Osama E. Rahma

First Author: Melissa Amber Burgess

First Author: John D. Powderly